Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy (NCT03755791)
A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy
🩺 Plain-English Summary (8th-Grade Level)
This Phase 3 study evaluates the safety and efficacy of cabozantinib in combination with atezolizumab versus the standard of care sorafenib in adults with advanced hepatocellular carcinoma (HCC) who have not received previous systemic anticancer therapy. A single-agent cabozantinib arm will be enrolled in which participants receive single agent cabozantinib in order to determine its contribution to the overall safety and efficacy of the combination with atezolizumab.
Who can join: Review the eligibility criteria below.
Location: Exelixis Clinical Site #208 — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (245 Sites)
Showing the first 25 of 245 sites.
- Exelixis Clinical Site #208 — Phoenix, Arizona
- Exelixis Clinical Site #159 — Tucson, Arizona
- Exelixis Clinical Site #44 — La Jolla, California
- Exelixis Clinical Site #112 — Los Angeles, California
- Exelixis Clinical Site #200 — Orange, California
- Exelixis Clinical Site #2 — Rialto, California
- Exelixis Clinical Site #207 — San Diego, California
- Exelixis Clinical Site #109 — San Francisco, California
- Exelixis Clinical Site #54 — San Francisco, California
- Exelixis Clinical Site #58 — Washington D.C., District of Columbia
- Exelixis Clinical Site #191 — Miami, Florida
- Exelixis Clinical Site #4 — Atlanta, Georgia
- Exelixis Clinical Site #195 — Chicago, Illinois
- Exelixis Clinical Site #120 — Chicago, Illinois
- Exelixis Clinical Site #6 — Baltimore, Maryland
- Exelixis Clinical Site #7 — Burlington, Massachusetts
- Exelixis Clinical Site #11 — Kansas City, Missouri
- Exelixis Clinical Site #5 — Kansas City, Missouri
- Exelixis Clinical Site #8 — St Louis, Missouri
- Exelixis Clinical Site #1 — Las Vegas, Nevada
- Exelixis Clinical Site #14 — New Brunswick, New Jersey
- Exelixis Clinical Site #76 — Albuquerque, New Mexico
- Exelixis Clinical Site #12 — Chapel Hill, North Carolina
- Exelixis Clinical Site #39 — Toledo, Ohio
- Exelixis Clinical Site #176 — Portland, Oregon
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hepatocellular Carcinoma
- TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients — Maywood, Illinois
- Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab — San Diego, California
- Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) — Baltimore, Maryland
- TheraSphere With Durvalumab and Tremelimumab for HCC — San Diego, California
- Blood Salvage in Orthotopic Liver Transplantation With HCC — Toronto, Ontario
- Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) — Prescott Valley, Arizona
Explore by condition: All Hepatocellular Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.